Biomark Capital Management buys $72,045,543 stake in Juno Therapeutics Inc (JUNO)

Juno Therapeutics Inc (JUNO) : Biomark Capital Management scooped up 603,364 additional shares in Juno Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 2,205,926 shares of Juno Therapeutics Inc which is valued at $72,045,543.Juno Therapeutics Inc makes up approximately 88.42% of Biomark Capital Management’s portfolio.

Other Hedge Funds, Including , Parametric Portfolio Associates boosted its stake in JUNO in the latest quarter, The investment management firm added 5,245 additional shares and now holds a total of 12,485 shares of Juno Therapeutics Inc which is valued at $407,760.Credit Suisse Ag reduced its stake in JUNO by selling 14,196 shares or 10.28% in the most recent quarter. The Hedge Fund company now holds 123,916 shares of JUNO which is valued at $4,047,097.State Of Wisconsin Investment Board boosted its stake in JUNO in the latest quarter, The investment management firm added 32,660 additional shares and now holds a total of 40,850 shares of Juno Therapeutics Inc which is valued at $1,334,161. Juno Therapeutics Inc makes up approx 0.01% of State Of Wisconsin Investment Board’s portfolio.State Board Of Administration Of Florida Retirement System boosted its stake in JUNO in the latest quarter, The investment management firm added 28,889 additional shares and now holds a total of 37,223 shares of Juno Therapeutics Inc which is valued at $1,171,036.Public Employees Retirement Association Of Colorado boosted its stake in JUNO in the latest quarter, The investment management firm added 1,633 additional shares and now holds a total of 10,824 shares of Juno Therapeutics Inc which is valued at $334,786.

Juno Therapeutics Inc closed down -0.45 points or -1.39% at $31.81 with 7,24,471 shares getting traded on Monday. Post opening the session at $32.19, the shares hit an intraday low of $31.23 and an intraday high of $32.475 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Juno Therapeutics Inc reported $-0.64 EPS for the quarter, missing the analyst consensus estimate by $ -0.05 based on the information available during the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.59. The company had revenue of $27.60 million for the quarter, compared to analysts expectations of $9.80 million. The company’s revenue was up 121.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.35 EPS.

Many Wall Street Analysts have commented on Juno Therapeutics Inc. Shares were Reiterated by Maxim Group on Aug 5, 2016 to “Buy” and Lowered the Price Target to $ 50 from a previous price target of $80 .Shares were Reiterated by FBR Capital on Jul 8, 2016 to “Outperform” and Lowered the Price Target to $ 61 from a previous price target of $73 .Shares were Downgraded by JP Morgan on Jul 8, 2016 to ” Neutral” and Lowered the Price Target to $ 39 from a previous price target of $63 .

Juno Therapeutics Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates JCAR015 JCAR017 and JCAR014 utilize CAR technology to target CD19 a protein expressed on the surface of various B cell leukemias and lymphomas. Juno’s other product candidates include JCAR018: CD22 JCAR023: L1CAM (CD171) JCAR020: MUC-16 / IL-12 ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML myelodysplasic syndrome and chronic myeloid leukemia.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *